{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:58:22Z","timestamp":1774418302640,"version":"3.50.1"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ctrv.2020.102101","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T12:08:03Z","timestamp":1598357283000},"page":"102101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Is DNA repair a potential target for effective therapies against malignant mesothelioma?"],"prefix":"10.1016","volume":"90","author":[{"given":"Ilaria","family":"Fuso Nerini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Roca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Mannarino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Frapolli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"D'Incalci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2020.102101_b0005","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02384-2017","article-title":"Variation in incidence trends of malignant pleural mesothelioma in Europe","volume":"51","author":"Ahmed","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ctrv.2020.102101_b0010","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/bjc.2017.22","article-title":"Prognostication and monitoring of mesothelioma using biomarkers: a systematic review","volume":"116","author":"Arnold","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2020.102101_b0015","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2020.102101_b0020","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2020.102101_b0025","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2020.102101_b0030","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res"},{"issue":"271\u2013281","key":"10.1016\/j.ctrv.2020.102101_b0035","article-title":"Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines","volume":"6","author":"Ellrott","year":"2018","journal-title":"Cell Syst"},{"key":"10.1016\/j.ctrv.2020.102101_b0040","first-page":"99","article-title":"Distinct spectrum of mutations induced by crocidolite asbestos: clue for 8-hydroxydeoxyguanosine-dependent mutagenesis in vivo","volume":"62","author":"Unfried","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102101_b0045","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jtho.2016.05.020","article-title":"The genetic landscape of malignant pleural mesothelioma: results from massively parallel sequencing","volume":"11","author":"Hylebos","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102101_b0050","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.canlet.2011.08.021","article-title":"DNA repair systems in malignant mesothelioma","volume":"312","author":"Toumpanakis","year":"2011","journal-title":"Cancer Lett"},{"issue":"239\u2013254","key":"10.1016\/j.ctrv.2020.102101_b0055","article-title":"Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas","volume":"23","author":"Knijnenburg","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.ctrv.2020.102101_b0060","series-title":"DNA repair and cancer: from bench to clinic","author":"Madhusudan","year":"2013"},{"key":"10.1016\/j.ctrv.2020.102101_b0065","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.molcel.2020.04.035","article-title":"Biomarker-guided development of DNA repair inhibitors","volume":"78","author":"Cleary","year":"2020","journal-title":"Mol Cell"},{"key":"10.1016\/j.ctrv.2020.102101_b0070","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102101_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2013.04.018","article-title":"A genome-wide association study for malignant mesothelioma risk","volume":"82","author":"Cadby","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2020.102101_b0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061253","article-title":"Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study","volume":"8","author":"Matullo","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2020.102101_b0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41525-019-0087-6","article-title":"High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer","volume":"4","author":"Bertelsen","year":"2019","journal-title":"NPJ Genom Med"},{"key":"10.1016\/j.ctrv.2020.102101_b0090","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.mrfmmm.2006.02.005","article-title":"Polymorphisms in DNA repair genes as risk factors for asbestos-related malignant mesothelioma in a general population study","volume":"599","author":"Dianzani","year":"2006","journal-title":"Mutat Res"},{"key":"10.1016\/j.ctrv.2020.102101_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21124327","article-title":"Inherited genetic mutations and polymorphisms in malignant mesothelioma: a comprehensive review","volume":"21","author":"Panou","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2020.102101_b0100","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1016\/j.febslet.2013.10.035","article-title":"BAP1 is phosphorylated at serine 592 in S-phase following DNA damage","volume":"587","author":"Eletr","year":"2013","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ctrv.2020.102101_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20020429","article-title":"BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment","volume":"20","author":"Guazzelli","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2020.102101_b0110","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jtho.2019.12.111","article-title":"Novel germline mutations in DNA damage repair in patients with malignant pleural mesotheliomas","volume":"15","author":"Guo","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102101_b0115","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/jnci\/djy171","article-title":"Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide","volume":"110","author":"Walpole","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2020.102101_b0120","doi-asserted-by":"crossref","first-page":"270","DOI":"10.21037\/tlcr.2017.05.03","article-title":"BAP1, a tumor suppressor gene driving malignant mesothelioma","volume":"6","author":"Cheung","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102101_b0125","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/0008-5472.CAN-15-0295","article-title":"Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer","volume":"76","author":"Ohar","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102101_b0130","doi-asserted-by":"crossref","first-page":"13432","DOI":"10.1073\/pnas.1612074113","article-title":"High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma","volume":"113","author":"Yoshikawa","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2020.102101_b0135","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2020.102101_b0140","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/onc.2015.243","article-title":"Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma","volume":"35","author":"Napolitano","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2020.102101_b0145","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/0008-5472.CAN-14-1328","article-title":"Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102101_b0150","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1158\/0008-5472.CAN-15-3371","article-title":"Bap1 is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations","volume":"76","author":"Kadariya","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102101_b0155","doi-asserted-by":"crossref","first-page":"34179","DOI":"10.1074\/jbc.M109.046755","article-title":"The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1","volume":"284","author":"Machida","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2020.102101_b0160","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1128\/MCB.01517-08","article-title":"Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1","volume":"29","author":"Misaghi","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2020.102101_b0165","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/gcc.22670","article-title":"Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes","volume":"57","author":"Betti","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ctrv.2020.102101_b0170","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102101_b0175","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.mrfmmm.2009.09.003","article-title":"Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolism","volume":"671","author":"Gemignani","year":"2009","journal-title":"Mutat Res"},{"key":"10.1016\/j.ctrv.2020.102101_b0180","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1073\/pnas.0712399105","article-title":"Transcriptome sequencing of malignant pleural mesothelioma tumors","volume":"105","author":"Sugarbaker","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2020.102101_b0185","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/mutage\/ger020","article-title":"Asbestos exposure affects poly(ADP-ribose) polymerase-1 activity: role in asbestos-induced carcinogenesis","volume":"26","author":"Tomasetti","year":"2011","journal-title":"Mutagenesis"},{"key":"10.1016\/j.ctrv.2020.102101_b0190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mrfmmm.2011.01.001","article-title":"XRCC1 and ERCC1 variants modify malignant mesothelioma risk: a case-control study","volume":"708","author":"Betti","year":"2011","journal-title":"Mutat Res"},{"key":"10.1016\/j.ctrv.2020.102101_b0195","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2478\/raon-2019-0016","article-title":"The influence of genetic variability of DNA repair mechanisms on the risk of malignant mesothelioma","volume":"53","author":"Levpuscek","year":"2019","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.ctrv.2020.102101_b0200","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/mutage\/gel016","article-title":"Possible involvement of XPA in repair of oxidative DNA damage deduced from analysis of damage, repair and genotype in a human population study","volume":"21","author":"Dusinsk\u00e1","year":"2006","journal-title":"Mutagenesis"},{"key":"10.1016\/j.ctrv.2020.102101_b0205","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.humpath.2011.12.012","article-title":"Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature","volume":"43","author":"Karamurzin","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2020.102101_b0210","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2020.102101_b0215","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.79.0352","article-title":"A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations","author":"Pastorino","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102101_b0220","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2020.102101_b0225","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.jtho.2018.07.015","article-title":"Mismatch repair protein defects and microsatellite instability in malignant pleural mesothelioma","volume":"13","author":"Arulananda","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102101_b0230","doi-asserted-by":"crossref","DOI":"10.1007\/s12094-019-02275-9","article-title":"Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients","author":"Cedr\u00e9s","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ctrv.2020.102101_b0235","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.lungcan.2010.05.008","article-title":"Methylation of MGMT in malignant pleural mesothelioma occurs in a subset of patients and is associated with the T allele of the rs16906252 MGMT promoter SNP","volume":"71","author":"Kristensen","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2020.102101_b0240","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ctrv.2020.102101_b0245","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12885-019-5314-0","article-title":"Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro","volume":"19","author":"Borchert","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2020.102101_b0250","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/annonc\/mdr324","article-title":"The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma","volume":"23","author":"Er\u010dulj","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102101_b0255","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/JTO.0b013e318233d6a9","article-title":"Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival","volume":"7","author":"Zimling","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"1539\u20131546","key":"10.1016\/j.ctrv.2020.102101_b0260","article-title":"Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery","volume":"149","author":"Frischknecht","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"558\u2013567","key":"10.1016\/j.ctrv.2020.102101_b0265","article-title":"ERCC1, MLH1, MSH2, MSH6, and \u03b2III-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma","volume":"14","author":"Ting","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2020.102101_b0270","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.7150\/jca.16390","article-title":"Screening of pleural mesotheliomas for DNA-damage repair players by digital gene expression analysis can enhance clinical management of patients receiving platin-based chemotherapy","volume":"7","author":"Walter","year":"2016","journal-title":"J Cancer"},{"key":"10.1016\/j.ctrv.2020.102101_b0275","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cllc.2012.09.003","article-title":"Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma","volume":"14","author":"Kao","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2020.102101_b0280","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2009.25.9275","article-title":"Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy","volume":"28","author":"Righi","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102101_b0285","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/1078-0432.CCR-10-2873","article-title":"Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed\/carboplatin","volume":"17","author":"Zucali","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102101_b0290","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1097\/JTO.0b013e3182653d31","article-title":"DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy","volume":"7","author":"Er\u010dulj","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102101_b0295","first-page":"2557","article-title":"XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency","volume":"59","author":"Lunn","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102101_b0300","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1093\/nar\/gkh872","article-title":"Repair of U\/G and U\/A in DNA by UNG2-associated repair complexes takes place predominantly by short-patch repair both in proliferating and growth-arrested cells","volume":"32","author":"Akbari","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ctrv.2020.102101_b0305","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bcp.2008.05.019","article-title":"Uracil in DNA: consequences for carcinogenesis and chemotherapy","volume":"76","author":"Berger","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ctrv.2020.102101_b0310","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lungcan.2009.03.016","article-title":"Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets","volume":"67","author":"R\u00f8e","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2020.102101_b0315","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a003566","article-title":"Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response","volume":"5","author":"Lund-Andersen","year":"2019","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"10.1016\/j.ctrv.2020.102101_b0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040521","article-title":"Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma","volume":"7","author":"R\u00f8e","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2020.102101_b0325","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/1535-7163.MCT-19-0356","article-title":"Functional genomic screen in mesothelioma reveals that loss of function of BRCA1-associated protein 1 induces chemoresistance to ribonucleotide reductase inhibition","volume":"19","author":"Okonska","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2020.102101_b0330","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-017-3401-y","article-title":"Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition","volume":"80","author":"Srinivasan","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2020.102101_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2019.08.594","article-title":"Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by temozolomide in cells with high-Schlafen 11 and Low-O6-methylguanine-DNA methyltransferase expression","author":"Rathkey","year":"2019","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ctrv.2020.102101_b0340","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature22798","article-title":"BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation","volume":"546","author":"Bononi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2020.102101_b0345","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jtho.2017.03.023","article-title":"A novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair","volume":"12","author":"Parrotta","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102101_b0350","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lungcan.2019.07.011","article-title":"Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma","volume":"135","author":"Morra","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2020.102101_b0355","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/jcmm.12000","article-title":"PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT\/mTOR axis via SIRT1","volume":"17","author":"Pinton","year":"2013","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.ctrv.2020.102101_b0360","doi-asserted-by":"crossref","first-page":"9054","DOI":"10.1200\/JCO.2020.38.15_suppl.9054","article-title":"Phase II study of olaparib in malignant mesothelioma (MM) to correlate efficacy with germline and somatic mutations in DNA repair genes","volume":"38","author":"Hassan","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2020.102101_b0365","doi-asserted-by":"crossref","first-page":"9057","DOI":"10.1200\/JCO.2020.38.15_suppl.9057","article-title":"MiST1: a phase IIa trial of rucaparib in patients harbouring BAP1\/BRCA1 deficient relapsed malignant mesothelioma","volume":"38","author":"Fennell","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2020.102101_b0370","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/ijc.28213","article-title":"Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis\u00ae (PM00104)","volume":"133","author":"Romano","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2020.102101_b0375","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00280-015-2918-1","article-title":"Unique features of trabectedin mechanism of action","volume":"77","author":"Larsen","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2020.102101_b0380","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41416-019-0550-2","article-title":"Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin","volume":"121","author":"Bello","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2020.102101_b0385","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1158\/1535-7163.MCT-15-0846","article-title":"Trabectedin is active against malignant pleural mesothelioma cell and xenograft models and synergizes with chemotherapy and Bcl-2 inhibition in vitro","volume":"15","author":"Hoda","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2020.102101_b0390","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1158\/1078-0432.CCR-13-1880","article-title":"First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors","volume":"20","author":"Elez","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102101_b0395","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.lungcan.2016.07.012","article-title":"Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: report of two cases","volume":"102","author":"Metaxas","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2020.102101_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2019.12.009","article-title":"Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17\/16)","author":"Metaxas","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102101_b0405","article-title":"Trabectedin in malignant pleural mesothelioma: results from the multicentre, single arm, phase II ATREUS Study","author":"Cortinovis","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2020.102101_b0410","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102101_b0415","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ctrv.2020.102101_b0420","first-page":"1157","article-title":"Role of evaluating tumor-infiltrating lymphocytes, programmed death-1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma","volume":"55","author":"Losi","year":"2019","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ctrv.2020.102101_b0425","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13073-019-0620-3","article-title":"BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma","volume":"11","author":"Shrestha","year":"2019","journal-title":"Genome Med"},{"key":"10.1016\/j.ctrv.2020.102101_b0430","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1200\/JCO.18.02050","article-title":"Moving from poly (ADP-Ribose) polymerase inhibition to targeting DNA repair and DNA damage response in cancer therapy","volume":"37","author":"Gourley","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220301390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220301390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:23:39Z","timestamp":1759656219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737220301390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":86,"alternative-id":["S0305737220301390"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102101","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is DNA repair a potential target for effective therapies against malignant mesothelioma?","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102101"}}